Nyumbani › Kisukari cha Aina ya 1
Majaribio ya kliniki ya Kisukari cha Aina ya 1 yanayovutia washiriki nchini Marekani
Masomo 138 ya Kisukari cha Aina ya 1 yanavutia washiriki katika vituo vya Marekani nzima.
Miji yenye masomo mengi
- Aurora, COUtafiti 23
- Boston, MAUtafiti 21
- Seattle, WAUtafiti 18
- Chicago, ILUtafiti 16
- New Haven, CTUtafiti 15
- New York City, NYUtafiti 15
- Indianapolis, INUtafiti 14
- San Francisco, CAUtafiti 14
- Miami, FLUtafiti 13
- Gainesville, FLUtafiti 12
- Philadelphia, PAUtafiti 11
- Atlanta, GAUtafiti 11
- Minneapolis, MNUtafiti 10
- Durham, NCUtafiti 10
- Houston, TXUtafiti 9
- Charlottesville, VAUtafiti 9
- Nashville, TNUtafiti 8
- Orlando, FLUtafiti 7
- Cleveland, OHUtafiti 7
- Dallas, TXUtafiti 7
- Pittsburgh, PAUtafiti 7
- Baltimore, MDUtafiti 6
- Columbus, OHUtafiti 6
- Buffalo, NYUtafiti 6
- Kansas City, MOUtafiti 6
- Los Angeles, CAUtafiti 6
- San Diego, CAUtafiti 6
- Tampa, FLUtafiti 5
- Jacksonville, FLUtafiti 5
- Detroit, MIUtafiti 5
- Memphis, TNUtafiti 4
- Rochester, MNUtafiti 4
- Louisville, KYUtafiti 4
- Mountain View, CAUtafiti 4
- Baldwin Park, CAUtafiti 4
- Cincinnati, OHUtafiti 3
- Salt Lake City, UTUtafiti 3
- Ann Arbor, MIUtafiti 3
- The Bronx, NYUtafiti 3
- Portland, ORUtafiti 3
Kwa jimbo
- ArizonaUtafiti 3
- CaliforniaUtafiti 37
- ColoradoUtafiti 24
- ConnecticutUtafiti 16
- FloridaUtafiti 30
- GeorgiaUtafiti 13
- IllinoisUtafiti 16
- IndianaUtafiti 14
- KentuckyUtafiti 6
- MarylandUtafiti 6
- MassachusettsUtafiti 21
- MichiganUtafiti 8
- MinnesotaUtafiti 13
- MissouriUtafiti 9
- New YorkUtafiti 23
- North CarolinaUtafiti 12
- OhioUtafiti 13
- OregonUtafiti 3
- PennsylvaniaUtafiti 13
- TennesseeUtafiti 11
- TexasUtafiti 16
- UtahUtafiti 5
- VirginiaUtafiti 10
- WashingtonUtafiti 20
- WisconsinUtafiti 3
Masomo yaliyosasishwa hivi karibuni
Maandishi rasmi ya utafiti (Kiingereza)
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
InaajiriHatua 1Wajitolea wenye afya wanakaribishwa
Umri 18 hadi 70 · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT07675590Finding Immune Nascent Type 1 Diabetes
InaajiriWajitolea wenye afya wanakaribishwa
Umri 1 hadi 99 · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT07663136Starting Technology in At Risk Type 1 Diabetes Study
Inaajiri
Umri 18 na zaidi · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT06453928ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
Inaajiri
Umri 8 hadi 21 · Jinsia zote · Imesasishwa 23 Sep 2026 · NCT05463289A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
InaajiriHatua 1
Umri 18 hadi 70 · Jinsia zote · Imesasishwa 23 Sep 2026 · NCT07803744App-Based Certified Diabetes Education Therapy (AB-CDE)
Inaajiri
Umri 18 na zaidi · Jinsia zote · Imesasishwa 23 Sep 2026 · NCT07282639A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
InaajiriHatua 3
Umri 1 hadi 35 · Jinsia zote · Imesasishwa 22 Sep 2026 · NCT07222137A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
InaajiriHatua 3
Umri 1 hadi 35 · Jinsia zote · Imesasishwa 22 Sep 2026 · NCT07222332Type 1 Diabetes Extension Study
InaajiriUtafiti wa uchunguzi
Umri 8 hadi 35 · Jinsia zote · Imesasishwa 18 Sep 2026 · NCT02734277METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
InaajiriHatua 2
Umri 18 hadi 69 · Jinsia zote · Imesasishwa 15 Sep 2026 · NCT07699380A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
InaajiriHatua 3
Umri 1 hadi 25 · Jinsia zote · Imesasishwa 14 Sep 2026 · NCT07088068CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
InaajiriHatua 1/2
Umri 12 hadi 35 · Jinsia zote · Imesasishwa 11 Sep 2026 · NCT06783309Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
InaajiriHatua 2
Umri 4 hadi 34 · Jinsia zote · Imesasishwa 9 Sep 2026 · NCT07216391The iLet Experience Study
InaajiriUtafiti wa uchunguzi
Umri 6 na zaidi · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT06891898Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
InaajiriHatua 2
Umri 8 hadi 45 · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT07142252Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes
Inaajiri
Umri 16 hadi 50 · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT05540704C-Carbs: A CGM-guided Approach to Teaching Carb Awareness
Inaajiri
Umri 18 na zaidi · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT07807280A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
InaajiriHatua 1/2
Umri 9 hadi 20 · Jinsia zote · Imesasishwa 2 Sep 2026 · NCT07061574Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
Inaajiri
Umri 8 hadi 65 · Jinsia zote · Imesasishwa 1 Sep 2026 · NCT05268250A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
InaajiriHatua 3
Umri 18 hadi 65 · Jinsia zote · Imesasishwa 1 Sep 2026 · NCT04786262Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring
InaajiriWajitolea wenye afya wanakaribishwa
Umri 18 hadi 90 · Jinsia zote · Imesasishwa 28 Ago 2026 · NCT07254364Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
Inaajiri
Umri 18 hadi 80 · Jinsia zote · Imesasishwa 28 Ago 2026 · NCT07599982HLA Demographics Study in Adults With Type 1 Diabetes
InaajiriUtafiti wa uchunguzi
Umri 18 hadi 55 · Jinsia zote · Imesasishwa 28 Ago 2026 · NCT06860516Pilot Implementation Trial of Implementation Toolkits for Diabetes Coaching
InaajiriWajitolea wenye afya wanakaribishwa
Umri wote · Jinsia zote · Imesasishwa 27 Ago 2026 · NCT07766811Family Intervention for Black Teens With Type 1 Diabetes
Inaajiri
Umri 10 hadi 14 · Jinsia zote · Imesasishwa 27 Ago 2026 · NCT06275412Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.